$34.01
-4.42 (-11.50%)
Open$37.32
Previous Close$38.43
Day High$38.35
Day Low$33.81
52W High$44.00
52W Low$14.00
Volume—
Avg Volume39.5K
Market Cap140.60M
P/E Ratio—
EPS$-3.34
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
-1.3% upside
Current
$34.01
$34.01
Target
$33.56
$33.56
$24.17
$33.56 avg
$46.23
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 687.2K | 1.09M | 10.43M |
| Net Income | -12,476,417 | -17,738,981 | 2.46M |
| Profit Margin | -1,815.3% | -1,724.6% | 23.6% |
| EBITDA | -16,273,435 | -24,423,006 | 3.49M |
| Free Cash Flow | — | — | 3.25M |
| Rev Growth | -36.7% | -36.7% | +12.7% |
| Debt/Equity | — | — | 1.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |